Yes...and if that happens....watch its $6B market cap go down the drain! The suits on Wall Street won’t allow that to happen.
Don’t forget, the Patent holders / inventors of Exondys are on the ATL1102 Scientific Advisory Board
As patent holders no doubt they get royalty from Sarepta....you reckon Sue would be putting a few ‘what if?’ scenarios on whiteboard for ANP board re partnership?
If Exondys fails in the US, it will be a setback for everybody, most of all the DMD patients.
So many angles to this story.
How desperate is Sarepta?
Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-445
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.5¢ | $35.58K | 335.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 375558 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 41673 | 2 |
View Market Depth
| Last trade - 11.01am 18/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |